Alternatively, the development of a doxorubicin-DNA aptamer conjugate that specifically recognizes AnxA1 on the surface of cancer cells significantly enhanced targeted therapy against tumours in vivo [87]. The gene discussed is ANXA1; the disease is neoplasm.